Editas Medicine Clears First Human Trial of Gene Editor for High Cholesterol
Editas Medicine has received approval to begin a Phase 1/2 trial of EDIT-401, targeting patients who need additional LDL cholesterol reduction.
Editas Medicine has received regulatory clearance to begin the first-in-human clinical trial of EDIT-401, its investigational gene-editing therapy aimed at patients with hyperlipidemia who require additional lowering of low-density lipoprotein cholesterol, commonly known as LDL-C.
The approved study is structured as a Phase 1/2 clinical trial, a combined safety and early efficacy design typical of first-in-human programs. The trial will initiate dosing in patients whose LDL-C levels remain inadequately controlled despite existing treatment options, a population that represents a significant unmet medical need in cardiovascular disease management.
Read more X4 Pharmaceuticals Lands $150M Debt Facility With K2 HealthVentures →
EDIT-401 represents a notable step in the broader push to apply CRISPR-based gene-editing technology to metabolic conditions beyond rare genetic diseases, where most early gene-editing programs have been concentrated. The move signals Editas Medicine's effort to expand its pipeline into more common chronic conditions with large patient populations.
Hyperlipidemia, characterized by elevated lipid levels in the blood, is a leading risk factor for heart attack and stroke. Current standard-of-care options include statins and PCSK9 inhibitors, but a subset of patients still cannot achieve target LDL-C levels, underscoring the clinical rationale for novel approaches such as gene editing.
Continue reading at GlobeNewswire - Industry News on Financial Services.
